Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Comparison of (211)At-PRIT and (211)At-RIT of Ovarian Microtumors in a Nude Mouse Model

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Various functions of PBMC from colon cancer patients are not decreased compared to healthy blood donors.

    Research output: Contribution to journalJournal articleResearch

  1. Extraction of 211At from nitric acid solutions into various organic solvents for use as an α-source for radiation chemistry studies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. N-[2-(maleimido)ethyl]-3-(trimethylstannyl)benzamide, a molecule for radiohalogenation of proteins and peptides

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sofia H L Frost
  • Tom Bäck
  • Nicolas Chouin
  • Ragnar Hultborn
  • Lars Jacobsson
  • Jörgen Elgqvist
  • Holger Jensen
  • Per Albertsson
  • Sture Lindegren
View graph of relations
Abstract Purpose: Pretargeted radioimmunotherapy (PRIT) against intraperitoneal (i.p.) ovarian microtumors using avidin-conjugated monoclonal antibody MX35 (avidin-MX35) and (211)At-labeled, biotinylated, succinylated poly-l-lysine ((211)At-B-PL(suc)) was compared with conventional radioimmunotherapy (RIT) using (211)At-labeled MX35 in a nude mouse model. Methods: Mice were inoculated i.p. with 1×10(7) NIH:OVCAR-3 cells. After 3 weeks, they received PRIT (1.0 or 1.5 MBq), RIT (0.9 MBq), or no treatment. Concurrently, 10 additional animals were sacrificed and examined to determine disease progression at the start of therapy. Treated animals were analyzed with regard to presence of tumors and ascites (tumor-free fraction; TFF), 8 weeks after therapy. Results: Tumor status at baseline was advanced: 70% of sacrificed animals exhibited ascites. The TFFs were 0.35 (PRIT 1.0 MBq), 0.45 (PRIT 1.5 MBq), and 0.45 (RIT). The 1.5-MBq PRIT group exhibited lower incidence of ascites and fewer tumors >1 mm than RIT-treated animals. Conclusions: PRIT was as effective as RIT with regard to TFF; however, the size distribution of tumors and presence of ascites indicated that 1.5-MBq PRIT was more efficient. Despite advanced disease in many animals at the time of treatment, PRIT demonstrated good potential to treat disseminated ovarian cancer.
Original languageEnglish
JournalCancer Biotherapy & Radiopharmaceuticals
Volume28
Issue number2
Pages (from-to)108-114
ISSN1084-9785
DOIs
Publication statusPublished - 2013

ID: 36840766